Loading
companiesCompany
Relay Therapeutics
Relay Therapeutics uses computer simulations of how proteins move to design precise cancer pills. Its lead drug, zovegalisib, targets a mutated growth protein called PI3K-alpha in breast cancer while sparing the normal version.
Overview
Relay Therapeutics is a Cambridge, Massachusetts precision medicine company that combines computational modelling of protein motion with experimental chemistry. Its lead programme, zovegalisib (RLY-2608), is a mutant-selective, allosteric PI3K-alpha inhibitor that the company lists in phase 3 for PIK3CA-mutant breast cancer and in a phase 1/2 trial for vascular anomalies. RLY-8161, an NRAS inhibitor, is in a phase 1/2 trial in NRAS-mutant melanoma and other NRAS-mutant solid tumours. Lirafugratinib (RLY-4008), an FGFR2-selective inhibitor developed in FGFR2-fusion cholangiocarcinoma, was out-licensed to Elevar Therapeutics in December 2024. A non-oncology alpha-galactosidase A programme for Fabry disease is also listed. Relay completed its Nasdaq IPO in July 2020, selling 20 million shares at 20 US dollars per share according to its final prospectus.
Headquarters
Cambridge, MA, US
Scorecard
All companies#404of 1244 companies, score 9
- phase 3 +3
- targets +2
- modalities +2
- registry trials +2
0 approved, 1 in phase 3, 0 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · Final prospectus: 20 million shares at 20 US dollars per share, before the underwriters' option of up to 3 million additional shares | 2020 | $400M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · RLAY
Stage
Public
Website
Phase 3small molecule
Zovegalisib is an experimental small-molecule drug from Relay Therapeutics in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at PIK3CA / PI3K-alpha.
Notes
top- IPO gross proceeds computed from the prospectus (20 million shares at 20 US dollars); final amount including the option was not confirmed. Founding year not sourced. The ai-drug-design tag reflects the company's computational platform as described on its site.
Similar pages
- CompanyBasilea Pharmaceutica
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- PersonLipika Goyal
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- TrialFOENIX-CCA2
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- TrialFIRST-308
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
- TrialFIGHT-202
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- CompanyHarmonic Discovery
Shares AI-driven drug & target discovery, Small-molecule kinase inhibitors.
- CompanyTyra Biosciences
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
cancers
fronts
technologies
targets
drugs
Phase 3small molecule